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Abstract
Background and purpose: Previous studies suggest that mechanisms and outcomes in
patients with COVID-19-associated stroke differ from those in patients with non-COVID-
19-associated strokes, but there is limited comparative evidence focusing on these
populations. The aim of this study, therefore, was to determine if a significant association exists between COVID-19 status with revascularization and functional outcomes
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following thrombectomy for large vessel occlusion (LVO), after adjustment for potential
confounding factors.
Methods: A cross-sectional, international multicenter retrospective study was conducted
in consecutively admitted COVID-19 patients with concomitant acute LVO, compared to
a control group without COVID-19. Data collected included age, gender, comorbidities,
clinical characteristics, details of the involved vessels, procedural technique, and various
outcomes. A multivariable-adjusted analysis was conducted.
Results: In this cohort of 697 patients with acute LVO, 302 had COVID-19 while 395
patients did not. There was a significant difference (p < 0.001) in the mean age (in years)
and gender of patients, with younger patients and more males in the COVID-19 group. In
terms of favorable revascularization (modified Thrombolysis in Cerebral Infarction [mTICI]
grade 3), COVID-19 was associated with lower odds of complete revascularization (odds
ratio 0.33, 95% confidence interval [CI] 0.23–0.48; p < 0.001), which persisted on multivariable modeling with adjustment for other predictors (adjusted odds ratio 0.30, 95% CI
0.12–0.77; p = 0.012). Moreover, endovascular complications, in-hospital mortality, and
length of hospital stay were significantly higher among COVID-19 patients (p < 0.001).
Conclusion: COVID-19 was an independent predictor of incomplete revascularization
and poor functional outcome in patients with stroke due to LVO. Furthermore, COVID-19
patients with LVO were more often younger and had higher morbidity/mortality rates.
KEYWORDS

COVID-19, large vessel occlusion, morbidity, mortality, stroke

I NTRO D U C TI O N

sought to evaluate whether COVID-19 has an independent association with revascularization and functional outcomes following the

Since the first reported case in Wuhan, China, coronavirus disease

endovascular treatment.

2019 (COVID-19) has been prevalent globally, with approximately
45 million cases and 730,000 deaths in the United States, up to
October 8, 2021 [1]. According to the World Health Organization

M ATE R I A L S A N D M E TH O D S

(WHO), there have been over 241 million cases and almost 5 million
deaths worldwide [2]. Patients with COVID-19 are at higher risk of

An international multicenter retrospective study of consecutively

thrombotic events, with an estimated prevalence rate of 22%, which

admitted COVID-19 patients with concomitant acute LVOs was per-

can further increase to up to 43% after admission to the intensive

formed between February 25 and December 30, 2020, across 50

care unit [3]. Hypercoagulability in COVID-19 patients may be

international comprehensive stroke centers, from North America,

caused by disease-associated stasis, cytokine storm, dysfunctional

Europe and the Middle East.

endothelium, and platelet activation [3-5].

The institutional review boards of participating institutions re-

One form of thrombosis is acute ischemic stroke (AIS). The risk of

viewed and approved the study, and patient consent was waived

AIS in COVID-19 patients may be elevated approximately three- to

based on the de-identified retrospective protocol with minimal risk.

eightfold in the first 3 days of respiratory symptoms [6,7]. The re-

Diagnosis of COVID-19 was established using reverse-transcriptase

ported prevalence of stroke among COVID-19 patients varies from

PCR assays of nasopharyngeal samples for identification of SARS-

1.3% up to 4.9% and the rate of SARS CoV-2 infection among stroke

CoV-2. Data will be made available by the corresponding author to

admissions is estimated to be 3.3% [8-16]. While there have been a

qualified investigators upon reasonable request.

number of reports indicating an excess number of large vessel occlusion (LVO) strokes in patients with COVID-19 [8,17,18], there are
limited data on the safety and outcomes of acute revascularization

Data collection

of LVO in COVID-19 patients [19,20]. To address current limitations,
an international multicenter study was conducted to identify dif-

Data collected included age, gender, comorbidities, clinical charac-

ferences in the demographics and stroke characteristics of LVO pa-

teristics of the included COVID-19 patients, details of the involved

tients with COVID-19 versus without COVID-19. Furthermore, we

vessels, procedural technique, and selected outcome measures (e.g.,

4
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time was defined as the time from stroke onset to hospital arrival.
Procedure duration was calculated as the time difference between

The total cohort comprised 697 patients with LVO, 302 of whom

arterial access and sheath removal. COVID-19 severity was deter-

had concomitant COVID-19 (43.3%). Patients with COVID-19 had a

mined based on the score and classification provided by the World

younger mean age than those without COVID-19 (61.1 ± 15.7 years

Health Organization (WHO) [21]. In addition, classification of AIS

vs. 71.0 ± 15.8 years; p < 0.001), with a lower proportion of fe-

subtype was performed according to the Trial of Org 10,172 in Acute

male patients in the COVID-19 group (41.1% vs. 80.5%; p < 0.001).

Stroke Treatment (TOAST) criteria [22]. For the involved vessels, we

Functional status prior to stroke onset was significantly different,

used the same classification provided by our participating centers

with a lower proportion of functional independence in the COVID-19

based on what was reported as first, second, third, and forth.

group (mRS score 0–2: 65.6% vs. 96.2%; p < 0.001 [Table 1]).

Study endpoints

Comorbidities

Co-primary outcomes were: (i) optimal revascularization, defined as

Chronic heart disease (18.9% vs. 34.4%; p < 0.001) and atrial fibrilla-

modified Thrombolysis in Cerebral Infarction (mTICI) grade 3; (ii) un-

tion (21.2% vs. 38.2%; p < 0.001) were less common in patients with

favorable functional outcome, at discharge and at 90 days, defined as

COVID-19, while chronic liver disease (6.0% vs. 2.5%; p = 0.022) and

modified Rankin Scale (mRS) score 3–6; and (iii) mortality at 90 days.

type 2 diabetes mellitus (29.5% vs. 22.3%; p = 0.014) were more

Recanalization scoring was estimated without central imaging adju-

common. Hypertension, chronic lung disease and chronic kidney dis-

dication. Secondary outcomes were: (i) sICH, defined as reduction of

ease frequency did not differ between the groups (Table 1).

four points on the National Institute of Health Stroke Scale (NIHSS)
in association with any hemorrhage, at the judgment of the treating
clinician; (ii) NIHSS score 24 h following mechanical thrombectomy.

Statistical analysis

COVID-19 characteristics
The severity of COVID-19 at stroke onset was moderate in 73.3% of
cases, severe in 14.8% and critical in 11.9%. Cough was the most frequent presenting symptom (48.7%), followed by fever (45.9%), pneu-

All data were analyzed using R software version 4.1.1 using the pack-

monia (14.4%), and acute respiratory distress syndrome (20.0%).

ages “Rcmdr” and “glm2” [23]. Continuous variables are shown as

COVID-19 diagnosis was established in 66.1% of the patients prior

means and standard deviation, with skewness and kurtosis tests used

to stroke onset. The mean duration between COVID-19 symptoms

to evaluate the normal distribution, with comparisons made according

and stroke onset was 8.8 ± 11.4 days, and in 33.9% of the COVID-19

to COVID-19 status (COVID-19 vs. non-COVID-19) using independent

group, stroke was the initial manifestation of the COVID-19 disease.

t-tests or Mann–Whitney U-tests, as appropriate. Categorical variables
are reported as frequencies and percentages, with the chi-squared
test or Fisher's exact test used for comparisons, as appropriate. Finally,

Stroke characteristics

univariable logistic regression was used to test covariates predictive
of revascularization (mTICI grade 2b or 3), and unfavorable outcome

Cardioembolic etiology represented a lower proportion in the

(mRS score 3–6). Interaction and confounding were assessed through

COVID-19 group (12.9% vs. 49.6%), while large vessel atherosclero-

stratification and relevant expansion covariates. Whenever possi-

sis (37.6% vs. 16.5%) and cryptogenic stroke (16.8% vs. 0.0%) were

ble, factors predictive on univariable analysis (p < 0.05) were entered

observed at a higher proportion in the COVID-19 group (p < 0.001).

into a backward multivariable logistic regression analysis, and the ef-

The mean Albert Stroke Program Early Computed Tomography

fect of COVID-19 was assessed to be clinically relevant in all models.

Score (ASPECTS) at admission was lower in the COVID-19 group

Regression results are expressed as odds ratios (ORs) and 95% confi-

(7.8 ± 2.4 vs. 8.9 ± 1.5; p < 0.001). The mean number of involved ves-

dence intervals (95% CIs). A p value < 0.05 was taken to indicate signifi-

sels was comparable between the COVID-19 and non-COVID-19

cance for all statistical tests. The results presented here are reported

groups (1.4 ± 0.9 vs. 1.3 ± 0.5; p = 0.236). The detailed distribution of

in accordance with the Strengthening the Observational Reporting of

affected vessels is shown in Table 2.

Observational Studies guidelines. Missing data were not imputed.

Data availability

Stroke treatment
The mean duration of time from last known normal to access was

The relevant anonymized patient-level data are available on reason-

shorter in the COVID-19 group (357.4 ± 513.3 min vs. 474.4 ± 365.1

able request from the authors.

min; p = 0.009), while the mean door-to-arterial access duration
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TA B L E 1 Baseline characteristics of the patients with large vessel occlusion with and without COVID-19
Variables

Non-COVID-19

COVID-19

Total

(N = 395)

(N = 302)

(N = 697)

Mean (SD) age, years

71.0 (15.8)

61.1 (15.7)

67.1 (16.5)

<0.001*

Gender: female, n (%)

318 (80.5)

124 (41.1)

442 (63.4)

<0.001*

Pre-admission mRS score 0–2, n (%)

380 (96.2)

198 (65.6)

578 (82.9)

<0.001*

Mean (SD) NIHSS score at admission

14.3 (7.5)

17.2 (8.5)

15.4 (8.0)

<0.001*

p

Hypertension, n (%)

271 (68.8)

174 (57.6)

445 (63.8)

0.104

Chronic heart disease, n (%)

136 (34.4)

57 (18.9)

193 (27.7)

<0.001*

Chronic lung disease, n (%)

76 (19.2)

60 (19.9)

136 (19.5)

0.575

Chronic kidney disease, n (%)

43 (10.9)

28 (9.3)

71 (10.2)

0.791

Chronic liver disease, n (%)

10 (2.5)

18 (6.0)

28 (4.0)

0.022*

Diabetes mellitus (type 2), n (%)

88 (22.3)

89 (29.5)

177 (25.4)

0.014*

Atrial fibrillation, n (%)

151 (38.2)

64 (21.2)

215 (30.8)

<0.001*

New onset atrial fibrillation, n (%)

0 (0.0)

21 (7.0)

21 (3.0)

0.238

Note: Missing data count per variable: age, n = 53; gender n = 17; pre-admission mRS score, n = 70; NIHSS at admission, n = 72; hypertension, n = 40;
chronic heart disease, n = 24; chronic lung disease, n = 22; chronic kidney disease, n = 24; chronic liver disease, n = 22; diabetes mellitus (type 2),
n = 31; atrial fibrillation, n = 31; new onset atrial fibrillation, n = 417.
Abbreviations: mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation.
*Statistically significant.

was longer in the COVID-19 group (87.5 ± 63.5 min vs. 71.6 ± 80.0

versus non-COVID-19 patients (10.6% vs 59.0%; p < 0.001). Similarly,

min; p = 0.043). Intravenous tissue plasminogen activator (tPA) ad-

the mortality rate was more than twofold higher in the COVID-19

ministration was less common in the COVID-19 group (23.5% vs.

group (42.0% vs. 19.1; p ≤ 0.001 [Table 3]).

33.4%; p < 0.001). A higher proportion of mechanical thrombectomy procedures was performed under general anesthesia in
the COVID-19 group (31.5% vs. 19.1%; p < 0.001), while mean

Predictors of revascularization mTICI grade 3

thrombectomy pass number (1.8 ± 1.5 vs. 1.9 ± 1.2; p = 0.520),
first pass effect (53.3% vs. 49.1%; p = 0.395), and stenting rates

In the univariable model, absence of COVID-19 infection (OR 0.33,

(7.3% vs. 8.6%; p = 0.584) were comparable among the two groups

95% CI 0.23–0.48; p < 0.001), female gender (OR 2.56, 95% CI 1.78–

(Table 3). The mean duration of the procedure to achieve revascu-

3.69; p < 0.001), and higher ASPECTS (OR 1.15, 95% CI 1.04–1.27;

larization was prolonged in the COVID-19 group (62.2 ± 47.3 vs.

p = 0.007) were predictors of better revascularization (mTICI grade

51.9 ± 31.9; p = 0.002). Moreover, there was a higher proportion

3). Accounting for other possible cofounders, only COVID-19 status

of mTICI grade 3 outcomes in the control group (66.6% vs. 25.5%;

(OR 0.30, 95% CI 0.12–0.77; p = 0.012) and female sex (OR 2.83,

p < 0.001 [Table 3]).

95% CI 1.31–6.15; p = 0.008) were independent predictors (Table 4).

Complications, functional outcomes, and mortality

Predictors of unfavorable outcomes (mRS score 3–6)

The procedure-related complication rate was higher among

Unfavorable outcomes were higher with increasing age (OR 1.04,

COVID-19 patients (26.6% vs. 10.0%; p < 0.001), with 19.7% of the

95% CI 1.02–1.06; p < 0.001) and NIHSS score at admission (OR 1.10,

complications in the COVID-19 group being symptomatic. There

95% CI 1.06–1.15; p < 0.001). Accounting for possible confounders

was no significant difference in sICH (6.6% vs. 5.6%; p = 0.683)

(including pre-admission mRS score), age (OR 1.04, 95% CI 1.02–

nor in NIHSS score at 24 h after thrombectomy (11.9 ± 10.8 vs.

1.06; p < 0.001) and NIHSS score (OR 1.10, 95% CI 1.06–1.15;

12.2 ± 8.2; p = 0.807) between the COVID-19 and non-COVID-19

p < 0.001) persisted as independent risk factors for unfavorable out-

groups.

comes (Table 5). A sensitivity analysis including only patients with a

The length of hospital stay was longer in the COVID-19 group

pre-admission mRS score of 0–2, found higher rates of unfavorable

(15.5 ± 17.6 days vs. 8.4 ± 8.5 days; p < 0.001). Poor functional out-

outcome among COVID-19 patients at 3 months (OR 2.10, 95% CI

come (mRS score 3–6) at discharge was observed in a significantly

1.08–3.99; p = 0.025); however, this association was not significant

higher proportion of patients in the COVID-19 group (37.1% vs. 9.6%;

after controlling for other variables (OR 0.81, 95% CI 0.22–2.59;

p < 0.001), and favorable functional outcome (mRS 0–2) at 90-day

p = 0.731 [Table S1]). A summary of predictors of mTICI grade 3 and

follow-up was observed in a lower proportion of COVID-19 patients

mRS score 3–6 is presented in Figure S1.

6

|

DMYTRIW et al.

TA B L E 2 Summary of the included large vessel occlusions
Variables

Non-COVID-19

COVID-19

Total

(N = 395)

(N = 302)

(N = 697)

Large vessel atherosclerosis (50% or more
narrowing in an artery)

64 (16.5)

76 (37.6)

140 (23.8)

Cardioembolic

192 (49.6)

26 (12.9)

218 (37.0)

p

Stroke classification, n (%)
<0.001*

Other (dissection, hypercoagulable)

131 (33.8)

66 (32.7)

197 (33.5)

Cryptogenic

0 (0.0)

34 (16.8)

34 (5.8)

Mean (SD) number of vessels involved

1.3 (0.5)

1.4 (0.9)

1.4 (0.8)

0.236

35 (9.0)

9 (25.7)

44 (10.4)

<0.001*

Vessel involved, n (%)
ICA
MCA (M1 segment)

156 (40.2)

3 (8.6)

159 (37.6)

MCA (M2 segment)

89 (22.9)

3 (8.6)

92 (21.7)

ACA (A1 segment)

4 (1.0)

3 (8.6)

7 (1.7)

ACA (A2 segment)

4 (1.0)

15 (42.9)

19 (4.5)

Extracranial carotid

62 (16.0)

0 (0.0)

62 (14.7)

Basilar

24 (6.2)

2 (5.7)

26 (6.1)

MCA (M3/4 segments)

10 (2.6)

0 (0.0)

10 (2.4)

Vertebral

4 (1.0)

0 (0.0)

4 (0.9)

7 (8.5)

4 (7.4)

11 (8.1)

Second vessel involved (if more than one), n (%)
ICA
MCA (M1 segment)

39 (47.6)

10 (18.5)

49 (36.0)

MCA (M2 segment)

18 (22.0)

8 (14.8)

26 (19.1)

ACA (A1 segment)

5 (6.1)

13 (24.1)

18 (13.2)

ACA (A2 segment)

3 (3.7)

4 (7.4)

7 (5.1)

Extracranial carotid

0 (0.0)

3 (5.6)

3 (2.2)

Basilar

1 (1.2)

1 (1.9)

2 (1.5)

PCA

2 (2.4)

6 (11.1)

8 (5.9)

MCA (M3/4 segments)

6 (7.3)

4 (7.4)

10 (7.4)

Vertebral

1 (1.2)

1 (1.9)

2 (1.4)

MCA (M1 segment)

6 (31.6)

2 (50.0)

8 (34.8)

MCA (M2 segment)

5 (26.3)

1 (25.0)

6 (26.1)

0.002*

Third vessel involved (if more than two), n (%)

ACA (A1 segment)

7 (36.8)

0 (0.0)

7 (30.4)

ACA (A2 segment)

1 (5.3)

0 (0.0)

1 (4.3)

PCA

0 (0.0)

1 (25.0)

1 (4.3)

0.149

Fourth vessel involved (if more than three), n (%)
MCA (M1 segment)

0 (0.0)

8 (42.1)

8 (36.4)

MCA (M2 segment)

3 (100.0)

7 (36.8)

10 (45.5)

ACA (A1 segment)

0 (0.0)

3 (15.8)

3 (13.6)

PCA

0 (0.0)

1 (5.3)

1 (4.5)

0.244

Note: Missing data count per variable: stroke classification, n = 108; ASPECTS, n = 152; vessel involved, n = 273.
Abbreviations: ACA, anterior cerebral artery; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; COVID-19, coronavirus disease
2019; ICA, internal carotid artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; SD, standard deviation.
*Statistically significant.

DISCUSSION

to explore the impact of COVID-19 on interventional outcomes in
this population. From analyses of compiled cases from 50 institu-

Our global collaborative effort to pool data on patients with LVO

tions worldwide, our data suggest that COVID-19 patients with

during the COVID-19 pandemic provided us with the opportunity

concomitant LVO have poorer functional outcome and rates of
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TA B L E 3 Summary of the procedures performed and outcomes
Variables

Non-COVID-19

COVID-19

Total

(N = 395)

(N = 302)

(N = 697)

Mean (SD) door to groin time, min

71.6 (80.0)

87.5 (63.5)

76.7 (75.4)

0.043*

Mean (SD) LKN to groin time, min

474.4 (365.1)

357.4 (513.3)

442.8 (413.1)

0.009*

tPA given, n (%)

132 (33.4)

71 (23.5)

203 (29.1)

<0.001*

Mean (SD) number of passes during
thrombectomy

1.9 (1.2)

1.8 (1.5)

1.8 (1.3)

0.520

First pass effect, n (%)

194 (49.1)

161 (53.3)

279 (40.0)

0.395

Stenting, n (%)

34 (8.6)

22 (7.3)

56 (8.0)

0.584

Mean (SD) procedure duration, min

51.9 (31.9)

62.2 (47.3)

56.4 (39.6)

0.002*

Favorable revascularization (mTICI 2b-3)

337 (85.3)

154 (50.9)

491 (86.3)

<0.001*

Favorable revascularization (mTICI 3)

263 (66.6)

77 (25.5)

340 (48.8)

<0.001*
<0.001*

p

Complications during or after the procedure, n (%)
None

352 (90.0)

168 (73.4)

521 (83.9)

Asymptomatic

39 (10.0)

16 (6.9)

55 (8.9)

Symptomatic

0 (0.0)

45 (19.7)

45 (7.2)

sICH, n (%)

22 (5.6)

20 (6.6)

42 (6.0)

0.683

Mean (SD) NIHSS score 24 h post
thrombectomy

12.2 (8.2)

11.9 (10.8)

12.1 (9.1)

0.807

0–2

131 (33.2)

149 (49.3)

280 (40.2)

<0.001*

3–6

38 (9.6)

112 (37.1)

150 (21.5)

NA

226 (57.2)

41 (13.6)

267 (38.3)

0–2

233 (59.0)

32 (10.6)

265 (38.0)

3–6

73 (18.5)

18 (6.0)

91 (13.1)

NA

89 (22.5)

252 (83.4)

341 (48.9)

8.4 (8.5)

15.5 (17.6)

15.5 (17.5)

<0.001*

Home

81 (20.5)

41 (13.6)

122 (17.5)

<0.001*

Rehabilitation

173 (43.8)

56 (18.5)

229 (32.9)

Hospice

23 (5.8)

5 (1.7)

28 (4.0)

Nursing facility

57 (14.4)

17 (5.6)

74 (10.6)

Not reported/deceased

61 (15.4)

183 (60.6)

244 (35.0)

74 (19.1)

111 (42.0)

185 (28.4)

mRS score at discharge, n (%)

mRS score at 3 months follow-up, n (%)

Mean (SD) length of hospital stay, days

<0.001*

Discharge, n (%)

In-hospital mortality

<0.001*

Note: Missing data count per variable: door to groin, n = 271; LKN to groin, n  = 264; tPA given, n  = 80; number of passes, n  = 112; first pass effect,
n  = 144; stenting, n  = 65; procedure duration, n  = 102; favorable revascularization, n  = 127; complications, n  = 75, sICH, n  = 373; 24 h NIHSS,
n  = 161; mRS at discharge, n  = 267; mRS at 3 months; n  = 341; length of hospital stay, n  = 92; discharge, n  = 191.
Abbreviations: LKN, last known normal; mRS, modified Rankin Scale; mTICI, modified Treatment in Cerebral Infarction; NA, not available; NIHSS,
National Institutes of Health Stroke Scale; SD, standard deviation; sICH, symptomatic intracerebral hemorrhage; tPA, tissue plasminogen activator.
*Statistically significant.

revascularization compared to non-COVID-19 patients, with a mor-

LVO, less favorable functional outcome at follow-up, and increased

tality rate reaching up to 42%. The likelihood of achieving complete

mortality [19,30,31,32,33].

revascularization was reduced by 70%, compared to patients without

The underlying pathophysiology that drives poorer outcomes for

COVID-19, in our collaboration. Our data are supported by contem-

AIS in COVID-19 patients is subject to ongoing investigation. However,

porary reports of poorer outcomes in patients with AIS in the set-

it is likely that COVID-19 influences patient conditioning for post-

ting of COVID-19, albeit without controls, which is a key advantage

stroke recovery. Factors known to impede recovery after stroke in-

of our current report [24-30]. Similarly to the present study, other

clude patient demographic factors, baseline functional status, and

analyses also suggest that COVID-19 is an independent predictor of

comorbidities [34]. In addition, stroke characteristics including severity
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Predictors

Univariable

Multivariable

OR (95% CI)

OR (95% CI)

COVID status
Non-COVID-19

Reference

COVID-19

0.33 (0.23–0.48, p < 0.001*)

0.30 (0.12–0.77; p = 0.012*)

Mean (SD) age

1.01 (0.99–1.02; p = 0.306)

0.99 (0.97–1.01; p = 0.223)

TA B L E 4 Logistic regression for
possible predictors of complete
revascularization in patients with large
vessel occlusion during the COVID-19
pandemic (mTICI grade 3)

Gender
Male

Reference

Female

2.56 (1.78–3.69, p < 0.001*)

2.83 (1.31–6.15; p = 0.008*)

Pre-admission mRS score
0–2

Reference

3–6

1.48 (0.71–3.32; p = 0.313)

1.69 (0.35–12.64; p = 0.547)

0.98 (0.96–1.00; p = 0.064)

1.00 (0.96–1.05; p = 0.836)

NIHSS score at admission
Mean (SD)
Chronic liver disease
No

Reference

Yes

1.06 (0.41–2.93; p = 0.900)

1.39 (0.30–10.09; p = 0.701)

Diabetes
No

Reference

Yes

1.19 (0.81–1.77; p = 0.370)

2.78 (1.33–6.31; p = 0.010*)

1.15 (1.04–1.27; p = 0.007*)

1.14 (0.95–1.38; p = 0.153)

1.00 (0.99–1.00; p = 0.065)

1.00 (0.99–1.00; p = 0.249)

1.00 (1.00–1.00; p = 0.053)

1.00 (1.00–1.00; p = 0.906)

ASPECTS on admission
Mean (SD)
Door to groin time (min)
Mean (SD)
LKN to groin time (min)
Mean (SD)
tPA given
No

Reference

Yes

0.92 (0.64–1.31; p = 0.634)

0.77 (0.38–1.56; p = 0.472)

Abbreviations: ASPECTS, Alberta Stroke Program Early Computed Tomography Score; CI,
confidence interval; LKN, last known normal; mRS, modified rankin scale; NIHSS, National
Institutes of Health Stroke Scale; OR, odds ratio; tPA, tissue plasminogen activator; SD, standard
deviation.
*Statistically significant.

and extent of stroke, location of ischemic tissue, time lag to treatment,

mean age of the COVID-19 cohort was younger than that of controls

concomitant pathologies, and other complications all affect post-

by approximately 10 years, which corroborates prior reported find-

stroke recovery [34]. The physiological state secondary to COVID-19

ings from other non-controlled studies [8,27,28,30,31,65,66,67,68].

appears to further exacerbate damage caused by ischemia [35]. In par-

This apparent incidence is almost fourfold higher than those in the

ticular, the heightened prothrombotic and proinflammatory state of

general population. We also found a significantly higher representa-

COVID-19 may manifest in several ways, including AIS, vasculopathy,

tion of males in the COVID-19 group, which is consistent with previ-

myocarditis, arrhythmias, thrombotic microangiopathy, coagulopathy

ously reported non-controlled studies [28,30].

and thrombocytopenia, tropism to endothelial cells via angiotensin-

Elucidating the impact of COVID-19 on the onset and severity

converting enzyme (ACE)-2 receptor, and inhibition of angiotensin (1–

of AIS is also an important consideration in the clinical care of this

7) production [36-61]. It has been proposed that downregulation of

population. This is pertinent, given that 73.3% of the patients who

ACE-2, leading to both arteriopathy and thrombosis, may play a central

developed LVO with COVID-19 had moderate disease severity ac-

role in the development of stroke during COVID-19 [62-64].

cording to the WHO classification [21]. Their immune dysregulation

Understanding the characteristics of patients who develop LVO

may result in a cytokine storm, which is of pathophysiological signif-

in the setting of COVID-19 is important for prognosis and immediate

icance in the development of stroke in COVID-19 disease [69-71].

care. To achieve this, we performed one of the first comparative stud-

The time from initial COVID symptomatology to stroke onset was,

ies of COVID-19 and control patients with LVO. We found that the

on average, 9 days in our study [72]. The Global COVID-19 Stroke

|

THROMBECTOMY IN COVID-19 PATIENTS: CONTROLLED STUDY

TA B L E 5 Logistic regression for
possible predictors of unfavorable
outcomes (modified Rankin Scale score
3–6)

Predictors

Univariable

Multivariable

OR (95% CI; p value)

OR (95% CI; p value)

9

COVID status
Non-COVID

Reference

COVID

1.80 (0.94–3.36; p = 0.071)

0.82 (0.23–2.59; p = 0.743)

1.04 (1.02–1.06; p < 0.001*)

1.04 (1.02–1.06; p < 0.001*)

Age (years)
Mean (SD)
Gender
Male

Reference

Female

0.96 (0.56–1.69; p = 0.887)

1.04 (0.50–2.23; p = 0.923)

Pre-admission mRS score
0–2

Reference

3–6

2.58 (0.81–7.98; p = 0.096)

3.28 (0.93–11.72; p = 0.061)

1.10 (1.06–1.13; p < 0.001*)

1.10 (1.06–1.15; p < 0.001*)

NIHSS score at admission
Mean (SD)
Chronic liver disease
No

Reference

Yes

1.69 (0.43–5.73; p = 0.413)

1.80 (0.35–7.84; p = 0.443)

Diabetes
No

Reference

Yes

1.14 (0.64–1.98; p = 0.653)

0.95 (0.48–1.85; p = 0.894)

0.92 (0.81–1.05; p = 0.206)

0.96 (0.82–1.14; p = 0.640)

ASPECTS on admission
Mean (SD)
tPA given
No

Reference

Yes

0.87 (0.51–1.45; p = 0.588)

0.82 (0.44–1.49; p = 0.515)

Abbreviations: ASPECTS, Alberta Stroke Program Early Computed Tomography Score; COVID-19,
coronavirus disease 2019; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke
Scale; tPA, tissue plasminogen activator; SD, standard deviation.
*Statistically significant.

Registry reported a similar latency of approximately 7 days between

proinflammatory systemic state which may induce LVO. Additionally,

symptom onset and stroke [30]. The interval from symptom onset

the cerebral distribution of strokes was also considerably different.

to hospital presentation was lower in the COVID-19 group, which

Non-COVID-19 strokes were most frequently observed in the MCA-

may be consistent with previous studies that did not show a delay in

M1 distribution. However, COVID-19 LVO appeared more likely to

endovascular thrombectomy time metrics during the COVID-19 era

occur in the anterior cerebral artery, for reasons that are yet to be

[73,74]. Factors that can increase the risk of stroke include infection,

elucidated. It should be noted that a non-negligible portion of the

which can also concurrently worsen the severity of the stroke [75].

occlusion location data was not available in the current study.

There was a significant difference between stroke classification

When comparing our experience with those of other large anal-

according to TOAST criteria, with a higher proportion of patients

yses, we found that the Get With The Guidelines-Stroke (GWTG-

with cryptogenic stroke in the COVID-19 group [22]. In our interna-

Stroke) registry analysis reported comparable results in patients

tional experience, we found that stroke severity was generally worse

diagnosed with COVID-19. The authors reported a worse NIHSS

in the COVID-19 cohort compared to controls, based on ASPECTS,

score at presentation, and considerably greater proportions of pa-

NIHSS score at presentation, and the number of involved vessels.

tients with LVO stroke [31]. In our study, the rate of tPA adminis-

The etiology of strokes for patients with and without COVID-19 was

tration was higher amongst non-COVID-19 patients. This may be

also significantly different. Confirming the preliminary conclusions

related to several factors, but one contributor could have been bar-

of smaller non-controlled studies, we found that COVID-19 LVO was

riers to stroke care for COVID-19 patients. Consistent with other

associated with higher rates of strokes due to large vessel athero-

clinical cerebrovascular studies, there was a relative global decline

sclerosis or cryptogenic etiology, whereas non-COVID-19 LVO was

in intravenous thrombolysis, mechanical thrombectomy, ruptured

more likely to be cardioembolic in etiology [18,76,77]. This further

aneurysm treatment, and aneurysmal subarachnoid hemorrhage ad-

supports the suggestion that COVID-19 is a prothrombotic and

missions during the initial wave of the COVID-19 pandemic [15,78].
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The complexity of intervention and technical approach are other

value of institutional collaboration in addressing clinical questions in

factors to be considered for mechanical thrombectomy for LVO. We

a timely and robust manner. The study also has several limitations.

assessed relative complexity between COVID-19 and non-COVID-19

Its retrospective design means there is an element of selection bias,

groups by comparing indirect measures based on the duration of

particularly when patients are chosen for mechanical thrombectomy.

the procedure, number of vessels involved, number of passes, rate

Due to the stress on resources created by the COVID-19 pandemic,

of complete and favorable revascularization, and technical com-

some patients may not have received optimal advanced imaging and

plications. Our analysis suggests that having LVO with COVID-19

clinical follow-up, and, as such, there were missing data for several

was associated with more involved vessels, longer procedure du-

outcomes. Nevertheless, all missing data were within subsidiary

ration, and a lower rate of complete revascularization at the end of

variables. Occasionally, control for some cofounders was not pos-

the procedure, albeit with a similar number of passes per occlusion.

sible due to insufficient data in patient records. Future prospective

Furthermore, COVID-19 patients had a 70% lower likelihood of

studies are needed to obtain a higher level of evidence.

achieving mTICI grade 3. Our results are in line with those reported

In conclusion, COVID-19 was an independent predictor of in-

in prior non-controlled COVID-19 series and are consistent with his-

complete revascularization in patients with stroke due to LVO in this

toric mechanical thrombectomy data [8,67,68]. A possible explanation

controlled study. Patients are more often younger, more often male,

is the hypercoagulable state in COVID-19 patients, which may cause

and have higher morbidity/mortality rates.

re-occlusion. In addition, among the COVID-19 patients undergoing
thrombectomy, the intravascular clots were prone to fragment and
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